SIENQ vs. BBLG, NAOV, BTTX, HSTO, CMRA, ACORQ, BLPH, PTEIQ, OSA, and ADTX
Should you be buying Sientra stock or one of its competitors? The main competitors of Sientra include Bone Biologics (BBLG), NanoVibronix (NAOV), Better Therapeutics (BTTX), Histogen (HSTO), Comera Life Sciences (CMRA), Acorda Therapeutics (ACORQ), Bellerophon Therapeutics (BLPH), PolarityTE (PTEIQ), ProSomnus (OSA), and Aditxt (ADTX). These companies are all part of the "medical" sector.
Sientra (NASDAQ:SIENQ) and Bone Biologics (NASDAQ:BBLG) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends, valuation and community ranking.
Sientra has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500. Comparatively, Bone Biologics has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500.
Sientra and Bone Biologics both received 0 outperform votes by MarketBeat users.
Bone Biologics has lower revenue, but higher earnings than Sientra. Bone Biologics is trading at a lower price-to-earnings ratio than Sientra, indicating that it is currently the more affordable of the two stocks.
In the previous week, Bone Biologics had 4 more articles in the media than Sientra. MarketBeat recorded 5 mentions for Bone Biologics and 1 mentions for Sientra. Bone Biologics' average media sentiment score of 0.46 beat Sientra's score of 0.00 indicating that Bone Biologics is being referred to more favorably in the news media.
Bone Biologics has a net margin of 0.00% compared to Sientra's net margin of -65.93%. Sientra's return on equity of 0.00% beat Bone Biologics' return on equity.
17.1% of Sientra shares are owned by institutional investors. Comparatively, 34.3% of Bone Biologics shares are owned by institutional investors. 1.5% of Sientra shares are owned by company insiders. Comparatively, 13.0% of Bone Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Sientra and Bone Biologics tied by winning 6 of the 12 factors compared between the two stocks.
Get Sientra News Delivered to You Automatically
Sign up to receive the latest news and ratings for SIENQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SIENQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SIENQ vs. The Competition
Related Companies and Tools
